Pharmaceutical combinations comprising an anti-ly75 antibody

This disclosure relates generally to the fields of immunology and molecular biology. More specifically, pharmaceutical combinations are provided comprising (A) antibodies, or antigen-binding portions thereof, directed against LY75, and (B) a second anticancer entity; nucleic acids encoding antibody combinations; methods for preparing antibody combinations; and methods for treating diseases, such as cancers, mediated by LY75 expression or activity. (Automatic translation with Google Translate, no legal value)